Related references
Note: Only part of the references are listed.The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation
Jonathan Tward et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)
Dose-response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control
Rebecca G. Levin-Epstein et al.
RADIOTHERAPY AND ONCOLOGY (2021)
Prostate SBRT: Comparison the Efficacy and Toxicity of Two Different Dose Fractionation Schedules
Donald Blake Fuller et al.
FRONTIERS IN ONCOLOGY (2020)
Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: Toxicity in the FLAME randomized controlled trial
Evelyn M. Monninkhof et al.
RADIOTHERAPY AND ONCOLOGY (2018)
Prostate-specific antigen 5 Years following stereotactic Body radiation Therapy for low- and intermediate-risk Prostate cancer: an ablative Procedure?
Shaan Kataria et al.
FRONTIERS IN ONCOLOGY (2017)
Prostate specific antigen kinetics following robotic stereotactic body radiotherapy for localized prostate cancer
Thomas P. Kole et al.
ACTA ONCOLOGICA (2015)
Stereotactic Body Radiation Therapy Versus Intensity-Modulated Radiation Therapy for Prostate Cancer: Comparison of Toxicity
James B. Yu et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study
Alan Katz et al.
RADIATION ONCOLOGY (2014)
Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials
Christopher R. King et al.
RADIOTHERAPY AND ONCOLOGY (2013)
External validation of the pretreatment nomogram to predict acute urinary retention after 125I prostate brachytherapy
Ellen M. Roeloffzen et al.
BRACHYTHERAPY (2012)
American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy
Yoshiya Yamada et al.
BRACHYTHERAPY (2012)
HIGH-DOSE-RATE BRACHYTHERAPY AS A MONOTHERAPY FOR FAVORABLE-RISK PROSTATE CANCER: A PHASE II TRIAL
Maroie Barkati et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Dose-Fractionation Sensitivity of Prostate Cancer Deduced From Radiotherapy Outcomes of 5,969 Patients in Seven International Institutional Datasets: α/β = 1.4 (0.9–2.2) Gy
Raymond Miralbell et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes
Debra E. Freeman et al.
RADIATION ONCOLOGY (2011)
Comparison of Tumor Control and Toxicity Outcomes of High-dose Intensity-modulated Radiotherapy and Brachytherapy for Patients With Favorable Risk Prostate Cancer
Michael J. Zelefsky et al.
UROLOGY (2011)
Virtual HDRSM cyberknife treatment for localized prostatic carcinoma:: Dosimetry comparison with hdr brachytherapy and preliminary clinical observations
Donald B. Fuller et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer
Michael J. Zelefsky et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds
IS Grills et al.
JOURNAL OF UROLOGY (2004)
Share Paper
